← All trials
NCT05825625
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2023
- Primary completion
- Nov 1, 2029
- Completion date
- Feb 1, 2030
- First posted
- Apr 24, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IKF Klinische Krebsforschung GmbH am Krankenhaus NordwestLead sponsor
- Institut für Klinische Krebsforschung IKF GmbHStudy director
- RocheCollaborator
- University of HeidelbergCollaborator
- Institut für Klinische Krebsforschung IKF GmbHOfficial
- University of HeidelbergOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.